Ipatasertib Plus Pembrolizumab Boosts Response in First-Line R/M HNSCC

New data from a randomized Phase 2 study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting suggests that the addition of the AKT inhibitor ipatasertib to pembrolizumab (Keytruda) may significantly improve outcomes for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).

Jacob Thomas, MD, Assistant Professor of Clinical Medicine at the USC Norris Comprehensive Cancer Center, presented the findings, which highlighted a more than doubling of the overall response rate (ORR) when the combination was used as a first-line treatment.

The challenge of resistance in HNSCC

While pembrolizumab-based therapy remains the current standard of care for first-line R/M HNSCC, single-agent efficacy remains limited. In patients with a PD-L1 combined positive score (CPS) of 1 or higher, pembrolizumab monotherapy typically yields an ORR of approximately 19%, with a median overall survival of 13.6 months.

According to Thomas, primary and secondary resistance to PD-1 blockade in HNSCC may be driven by the abundance of regulatory T cells (Tregs) in the tumor microenvironment. Research indicates that PD-1 blockade can actually induce Treg activation through the AKT pathway, potentially hindering the immune response. Ipatasertib, an orally administered small-molecule inhibitor of all three isoforms of AKT, was hypothesized to overcome this by selectively inhibiting the proliferation of these immunosuppressive Tregs.

Study design and patient demographics

The study enrolled 52 patients with R/M HNSCC who had received no prior systemic treatment for their recurrent or metastatic disease. Participants were randomized 1:1 into two arms:

• Arm 1: Ipatasertib (400mg QD on days 1-14) plus pembrolizumab (200mg on day 1) in 21-day cycles.
• Arm 2: Pembrolizumab monotherapy (200mg on day 1) in 21-day cycles.

Patients were stratified by PD-L1 CPS scores (1-19 vs. 20+). The primary endpoints were progression-free survival (PFS) and safety. The study population had a median age of 67, was predominantly male (77%), and 60% of participants had a high PD-L1 expression (CPS 20+).

Efficacy results: A notable leap in response

The combination of ipatasertib and pembrolizumab showed "promising efficacy," according to the investigators. The ORR for the combination arm was 41%, compared to just 17% for the pembrolizumab monotherapy arm.

Even more striking was the depth of response. As of a data cutoff in May 2026, the complete response (CR) rate in the combination arm reached 26% (7 patients), whereas the monotherapy arm saw a CR rate of only 4.2% (1 patient).

The disease control rate was also substantially higher in the combination group (70% vs. 42%).

Regarding survival, the median PFS for the combination was 8.1 months, compared to 6.2 months for those receiving pembrolizumab alone. The 6-month PFS rate was 62.7% for the combination and 52.3% for the monotherapy.

Nursing implications: Managing the safety profile

For oncology nurses, understanding the safety profile of this new combination is critical for patient education and symptom management. The investigators concluded that the combination has an acceptable safety profile, though it does introduce additional toxicities compared to immunotherapy alone.

The most common treatment-related adverse events (TRAEs) occurring in at least 10% of subjects in the ipatasertib arm included:

• Diarrhea: 70.4% (mostly Grade 1 or 2)
• Fatigue: 44.4%
• Nausea: 40.7%
• Increased AST/ALT: 18.5% and 14.8%, respectively

Nurses should be prepared to manage gastrointestinal side effects, as diarrhea was the most prevalent AE. Notably, 37% of patients in the combination arm required drug interruptions, and 14.8% required dose reductions of ipatasertib to manage these toxicities. However, the discontinuation rate due to adverse events remained low and identical in both arms at 3.7%, suggesting that most toxicities were manageable with proactive intervention.

Looking ahead

The study concludes that adding an AKT inhibitor to PD-1 blockade may provide a potent new strategy for treating HNSCC. While pembrolizumab remains the backbone of therapy, the 41% ORR achieved with the addition of ipatasertib marks a significant potential advancement for patients with this aggressive malignancy.

Further analysis of secondary objectives, including changes in the tumor microenvironment and immune-cell populations in peripheral blood, is ongoing to better identify which patients may benefit most from this precision approach.

Reference

1. Thomas J, Bruce JY, Lorch J, et al. A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Presented at: 2026 ASCO Annual Meeting; May 29-June 2, 2026; Chicago, IL. Abstract 6006.